End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,601 MXN | -6.39% |
|
-.--% | -.--% |
26/06 | Redburn Atlantic Initiates Arkema at Buy | MT |
14/05 | Arkema: collaboration with ProLogium in batteries | CF |
Strengths
- With a P/E ratio at 10.31 for the current year and 9.05 for next year, earnings multiples are highly attractive compared with competitors.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.84 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 6.5B | - | ||
+0.73% | 99.64B | A- | ||
-11.98% | 58.77B | A- | ||
+75.71% | 48.81B | B | ||
+5.26% | 34.94B | B | ||
+0.61% | 31.15B | A- | ||
+3.47% | 18.62B | B- | ||
+17.33% | 17.44B | C+ | ||
+5.92% | 13.51B | B- | ||
-6.67% | 12.73B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AKE Stock
- AKE N Stock
- Ratings Arkema S.A.